| Περίληψη: | Defects in cell death pathways promote tumor development and progression, with potentially devastating consequences for cancer patients. Greater understanding of the defects occurring in cancer cells, and the unique characteristics of tumors which can make them vulnerable to cell death stimuli, offers tremendous opportunities for developing novel and effective anti-cancer therapies. In Cell Death in Cancer Biology and Treatment leading experts in the field provide a wealth of up-to-date knowledge regarding the molecular mechanisms and cell biological processes that control cell death. Each chapter also highlights recent advances in the translation of basic research findings into clinical trials. Beginning and established investigators alike will benefit from the thorough presentations of the most promising avenues for future development of cell death-based, anti-cancer strategies and agents. The volume begins with a detailed description of many of the cell death defects that have been identified in human tumor specimens. The unique bioenergetics of cancer cells, and the influence of the tumor microenvironment, autophagy, and cellular microRNAs on cancer cell death are then discussed, along with current progress in targeting these distinctive features and processes. Additional chapters describe recent advances, and the therapeutic benefits of targeting DNA repair pathways, protein chaperones, sphingolipid signaling, Bcl-2 family members, IAPs, death receptor signaling, the proteasome, and survival signaling emanating from the PI3K/AKT and RAS/RAF/MEK/ERK pathways. Finally, recent discoveries are presented regarding interactions between the immune system and dying cancer cells and the potential for optimizing these interactions to maximize anti-cancer activities. In summary, Cell Death in Cancer Biology and Treatment will be a valuable resource for scientists interested in cutting-edge understanding of aberrant cell death in cancer cells, and the multitude of innovative molecular targeting approaches that are actively being pursued to achieve selective activation of cell death in human malignancies.
|
|---|
